|
|
 |
|
Viewing report
|
|
|
|
China Pharmaceutical & Biotechnology Review
General Biologic, Feb 2012
The China Pharmaceutical & Biotechnology Review is a monthly publication covering all aspects of the industry, delivered to subscribers via email as a PDF document. From reimbursement policy and industry reform to newly registered drugs and emerging local players, the CPB Review sheds an insightful light on China's complex and opaque marketplace. Each issue includes news briefs reviewing the key developments of the previous month, in-depth analytical articles, exclusive interviews with industry executives, and research highlights. Included are profiles of companies, products, and influential personalities in the industry.
The CPB Review is geared towards healthcare industry professionals interested in keeping track of events in China, but who do not have a pressing need for daily information or historical search capabilities. The CPB Review synthesizes current events and bigger picture trends, making sense of the dizzying pace of change in the Chinese healthcare marketplace.
What do I get with a subscription?
- You get a PDF file monthly newsletter with all the news from the month, lead articles, and capital markets overview
- You get access to the news briefs headlines and full articles daily as they are created on www.gbipharma.com
- You get a weekly email that includes the headlines and links to the articles
- You get access to any pod casts or interviews GB conducts
Subscription Includes:
IN-DEPTH REPORTS
Proprietary reports on the latest trends in China's pharma industry
EXCLUSIVE INTERVIEWS
Learn what leaders in China's healthcare industry are doing to stay ahead in China
EXECUTIVE NEWS BRIEFS
Most inportant news briefs frome the month designed to be read for decision makers
UNIQUE INDUSTRY DATA
Information collected from our revolutionary SOURCE information platform
MONTHLY DELIVERIES
Available in PDF and print format
Latest Issues
Issue 51
Lead articles:
- A New Leaf: Beijing moves Traditional Chinese Medicine to the front burner
Rough Tendering: Growing dissatisfaction with the “Anhui Model”
- Ralf Altmeyer on Accelerating Global Biotech Companies via Advance BioChina
Issue 50
Lead articles:
- Can the Dragon and the Elephant Tango?
- Antibiotic abuse in China
- Ming-Wei Wang on China's Drug Discovery and Development
Issue 49
Lead articles:
- Is China Cleaning Up Its Act? Pharma and the recent pollution scandal
- Dogged by rabies: China bites back at a growing epidemic
- Alex Fowkes on R&D Business Development in China
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
SOURCE Select - China's Premier Pharma and Biotech Newswire
Chinese Pharma & Biotech Press Review
US Healthcare Reform: Impact and Implications for the Pharmaceutical and Biotech Industries
Top 10 Biotech Companies: Media Monitor
Bioinformatics Media Monitor
Biotechnology - Global Outlook
Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 5th edition
Biotechnology in India - An Indian Market Report
Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008
Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition
|
|
|
|
